Lisata Therapeutics (NASDAQ:LSTA) Trading Up 0.8% – Here’s What Happened

Lisata Therapeutics, Inc. (NASDAQ:LSTA)’s share price rose 0.8% during mid-day trading on Thursday . The company traded as high as $2.68 and last traded at $2.64. Approximately 19,329 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 81,272 shares. The stock had previously closed at $2.62.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Stock Performance

The firm has a market capitalization of $22.15 million, a PE ratio of -1.05 and a beta of 1.14. The firm has a fifty day moving average of $3.02 and a 200 day moving average of $2.99.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same period in the previous year, the business earned ($0.65) EPS. Research analysts forecast that Lisata Therapeutics, Inc. will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its holdings in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.